Malignant Pleural Mesothelioma
23 MALIGNANT PLEURAL MESOTHELIOMA Hamza Hashmi, MD A 70-year-old white man with past medical history of hypertension (HTN) and chronic obstructive pulmonary disease (COPD) presents with a persistent cough for…
CARDIOLOGY
Small Cell Lung Cancer Treatment: Early Stage
16 SMALL CELL LUNG CANCER TREATMENT: EARLY STAGE Victor van Berkel, MD, PhD • Neal E. Dunlap, MD • Matthew Fox, MD • Alden Klarer, MD, PhD • Kate Alyse…
Immunotoxicity
21 IMMUNOTOXICITY Amitoj Gill, MD • Rahul Gosain, MD This case involves a 68-year-old man diagnosed with metastatic non–small cell lung cancer (NSCLC) and adenocarcinoma histology with a programmed death…
Etiology of Lung Cancer
3 ETIOLOGY OF LUNG CANCER Goetz Kloecker, MD, MBA, MSPH, FACP • Brian Dong, MD • Rohit Kumar, MD Your 60-year-old female patient with metastatic non-small cell lung cancer never…
Prevention of Lung Cancer
9 PREVENTION OF LUNG CANCER Susanne M. Arnold, MD A 40-year-old African American male with a past medical history of hypertension and myocardial infarction and a 15 pack-year tobacco history…
History of Lung Cancer
1 HISTORY OF LUNG CANCER Goetz Kloecker, MD, MBA, MSPH, FACP A medical student reading about lung cancer notices that the number of lung cancer deaths has steadily increased worldwide….
Race is not a risk factor: Reframing discourse on racial health inequities in CVD prevention
We respectfully submit this letter in response to the March 2021 state-of-the-art review article “Ten things to know about ten cardiovascular disease risk factors” . Although the article effectively summarizes…
Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.
American physicians are now treating dyslipidemia according to a fifth iteration of national guidelines for the use of lipid-lowering therapies . These guidelines are developed with considerable care and deliberation…
Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States
Abstract Objective We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively…
